Cargando…

Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence

Non-alcoholic fatty liver disease (NAFLD) is a clinical condition characterized by lipid infiltration of the liver, highly prevalent in the general population affecting 25% of adults, with a doubled prevalence in diabetic and obese patients. Almost 1/3 of NAFLD evolves in Non-Alcoholic SteatoHepatit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cicero, Arrigo F. G., Colletti, Alessandro, Bellentani, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163782/ https://www.ncbi.nlm.nih.gov/pubmed/30142943 http://dx.doi.org/10.3390/nu10091153

Ejemplares similares

Nutraceutical Approach to Chronic Osteoarthritis: From Molecular Research to Clinical Evidence
por: Colletti, Alessandro, et al.
Publicado: (2021)

Is there an effective therapy available for non-alcoholic fatty liver disease?
por: Di Maso, Vittorio, et al.
Publicado: (2009)

Nutraceuticals and Hypertensive Disorders in Pregnancy: The Available Clinical Evidence
por: Fogacci, Silvia, et al.
Publicado: (2020)

Nutraceuticals as Modulators of Immune Function: A Review of Potential Therapeutic Effects
por: Medoro, Alessandro, et al.
Publicado: (2023)

Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2018)

Irisin Is Related to Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kosmalski, Marcin, et al.
Publicado: (2022)

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
por: Rong, Li, et al.
Publicado: (2023)

Effects of a Combined Nutraceutical on Lipid Pattern, Glucose Metabolism and Inflammatory Parameters in Moderately Hypercholesterolemic Subjects: A Double-blind, Cross-over, Randomized Clinical Trial
por: Cicero, Arrigo Francesco Giuseppe, et al.
Publicado: (2016)

In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kanuri, Giridhar, et al.
Publicado: (2013)

Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Schattenberg, Jörn M., et al.
Publicado: (2019)

Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Carneros, David, et al.
Publicado: (2020)

Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD)
por: Parameswaran, Madhangi, et al.
Publicado: (2021)

What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kosmalski, Marcin, et al.
Publicado: (2023)

Fatty Liver Index is a valid predictor of non-alcoholic fatty liver disease (NAFLD) in pregnancy
por: Koralegedara, Iresha Sandamali, et al.
Publicado: (2022)

Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
por: de Carvalho, Sylene Coutinho Rampche, et al.
Publicado: (2013)

Non-alcoholic fatty liver disease (NAFLD): a tale of fat and sugar?
por: Longato, Lisa
Publicado: (2013)

Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Saeed, Ali, et al.
Publicado: (2017)

Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort
por: Chalmers, Jane, et al.
Publicado: (2019)

Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19.
por: Bramante, Carolyn T., et al.
Publicado: (2020)

The Role of Resolvins, Protectins and Marensins in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Maciejewska-Markiewicz, Dominika, et al.
Publicado: (2021)

Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences
por: Tripodi, Armando, et al.
Publicado: (2022)

Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy
por: Yao, Pengyu, et al.
Publicado: (2022)

Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD)
por: Moghtadaie, Atie, et al.
Publicado: (2023)

The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Savic, Dragana, et al.
Publicado: (2020)

Nutraceutical Effects on Glucose and Lipid Metabolism in Patients with Impaired Fasting Glucose: A Pilot, Double-Blind, Placebo-Controlled, Randomized Clinical Trial on a Combined Product
por: Cicero, Arrigo Francesco Giuseppe, et al.
Publicado: (2017)

Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy
por: Colletti, Alessandro, et al.
Publicado: (2022)

Clinical features and metabolic complications for non-alcoholic fatty liver disease (NAFLD) in youth with obesity
por: Barbieri, Emiliano, et al.
Publicado: (2023)

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
por: Tacke, Frank, et al.
Publicado: (2021)

Can Diet Help Non-Obese Individuals with Non-Alcoholic Fatty Liver Disease (NAFLD)?
por: Merchant, Hamid A.
Publicado: (2017)

The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD)
por: Liu, Qing, et al.
Publicado: (2010)

Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
por: Abbas, Tahany, et al.
Publicado: (2020)

Macrophages and scavenger receptors in obesity‐associated non‐alcoholic liver fatty disease (NAFLD)
por: Kragh Petersen, Sine, et al.
Publicado: (2020)

Non-alcoholic fatty liver disease (NAFLD) is associated with dynamic changes in DNA hydroxymethylation
por: Lyall, Marcus J., et al.
Publicado: (2019)

Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Nier, Anika, et al.
Publicado: (2020)

Exercising in the COVID-19 era: implications in non-alcoholic fatty liver disease (NAFLD)
por: O'Gorman, Philip, et al.
Publicado: (2021)

Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review
por: Riazi, Kiarash, et al.
Publicado: (2022)

Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment
por: Guo, Xiangyu, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease, to struggle with the strangle: Oxygen availability in fatty livers
por: Anavi, Sarit, et al.
Publicado: (2017)

Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies
por: Balak, Deepak M W, et al.
Publicado: (2021)

Advances in Technologies for Highly Active Omega-3 Fatty Acids from Krill Oil: Clinical Applications
por: Colletti, Alessandro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3gqumd0q1oo1f8j7bmvj72tual